A groundbreaking ceremony was held Wednesday for the $1.2 billion National Bio and Agro-Defense Facility (NABF) currently under construction in Kansas.
AstraZeneca CEO Pascal Soriot is counting on the company's cancer drug pipeline to help it climb out of the revenue hole it has fallen into, and he figures his company needs more manufacturing capacity for the coming launches.
Rare disease drugmaker Alexion has found a lot to love in Ireland. Taking advantage of that country's generous tax rate, it has turned that country into its European base of operations. With a pipeline of new drugs brewing, the rare disease specialist now intends to build a new plant and add a couple hundred more workers there.
Animal health leader Zoetis is using a move out of the Amgen playbook, whacking on manufacturing to cut costs and appease an aggressive activist investor.
WuXi Biologics is embarking on construction of what will be the biggest biologics plant in China once it's completed--an event the company expects by the end of next year.
Mylan is recalling 8 lots of injectable cancer drugs, most of them manufactured for Pfizer, after particulate was discovered in vials.
J&J's Janssen unit is recalling one lot of Ortho-Cept contraceptive tablets because of the potential that the potency of the two active ingredients may not meet specifications, Health Canada reports.
After failing to sell its animal health production facility in St. Joseph, MO, Bayer HealthCare confirmed on Tuesday that it would close the site.
Getting too much of the pain reliever acetaminophen can be a serious issue, particularly for people with liver damage, and so U.K.-based Reckitt Benckiser thinks it best to recall 1.5 million bottles of Mucinex in the U.S. whose back labels don't match the front.
This past season's flu vaccines posted one of the worst efficacy rates in recent memory. That's partly because the viral strains they contained weren't the ones that ended up circulating. But on top of that, GlaxoSmithKline has uncovered some other effectiveness problems of its own--and now it's recalling a quadrivalent jab in a move that affects 1.7 million doses.